British Journal of Cancer - Table of Contents alert Volume 108 Issue 10

TABLE OF CONTENTS Volume 108, Issue 10 (1925-2196) Published online 28 May 2013 In this issue Minireview Clinical Studies Translational Therapeutics Molecular Diagnostics Genetics and Genomics Letters to the Editor Also new today Advance online publication Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement British Journal of Cancer presents: Guidelines for the Welfare and use of Animals in Cancer Research These NCRI guidelines define and encourage sharing of best practice in laboratory work. Already endorsed by leading scientists worldwide and widely cited, they should also be read and adopted by those making decisions about licensing, funding and publication of work involving animals.   Minireview Top Circulating microRNAs as potential new biomarkers for prostate cancer A Sita-Lumsden, D A Dart, J Waxman and C L Bevan Br J Cancer 2013 108: 1925-1930; advance online publication, April 30, 2013; 10.1038/bjc.2013.192 Abstract | Full Text Clinical Studies Top Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours W H Y Ling, P P Soe, A S L Pang and S-C Lee Br J Cancer 2013 108: 1931-1935; advance online publication, May 7, 2013; 10.1038/bjc.2013.225 Abstract | Full Text Are the UK oncology trainees adequately informed about the needs of older people with cancer? T Kalsi, S Payne, H Brodie, J Mansi, Y Wang and D Harari Br J Cancer 2013 108: 1936-1941; advance online publication, April 30, 2013; 10.1038/bjc.2013.204 Abstract | Full Text Does the ‘Liverpool Care Pathway’ facilitate an improvement in quality of care for dying cancer patients? C R Mayland, E M I Williams, J Addington-Hall, T F Cox and J E Ellershaw Br J Cancer 2013 108: 1942-1948; advance online publication, May 16, 2013; 10.1038/bjc.2013.203 Abstract | Full Text Class, race and ethnicity and information avoidance among cancer survivors R F McCloud, M Jung, S W Gray and K Viswanath Br J Cancer 2013 108: 1949-1956; advance online publication, May 16, 2013; 10.1038/bjc.2013.182 Abstract | Full Text Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102) N Katsumata, H Yoshikawa, H Kobayashi, T Saito, K Kuzuya, T Nakanishi, T Yasugi, N Yaegashi, H Yokota, S Kodama, T Mizunoe, M Hiura, T Kasamatsu, T Shibata and T Kamura on behalf of the Japan Clinical Oncology Group Br J Cancer 2013 108: 1957-1963; advance online publication, May 2, 2013; 10.1038/bjc.2013.179 Abstract | Full Text Patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy C E Olsson, N Pettersson, D Alsadius, U Wilderäng, S L Tucker, K-A Johansson and G Steineck Br J Cancer 2013 108: 1964-1970; advance online publication, April 30, 2013; 10.1038/bjc.2013.180 Abstract | Full Text Treatment of local–regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors E M Wever, E A M Heijnsdijk, G Draisma, C H Bangma, M J Roobol, F H Schröder and H J de Koning Br J Cancer 2013 108: 1971-1977; advance online publication, May 14, 2013; 10.1038/bjc.2013.198 Abstract | Full Text Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy D-W Lee, S-W Han, H J Lee, Y-Y Rhee, J M Bae, N-Y Cho, K-H Lee, T-Y Kim, D-Y Oh, S-A Im, Y-J Bang, S-Y Jeong, K J Park, J-G Park, G H Kang and T-Y Kim Br J Cancer 2013 108: 1978-1984; advance online publication, May 7, 2013; 10.1038/bjc.2013.232 Abstract | Full Text Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer L W-C Chow, B Xu, S Gupta, A Freyman, Y Zhao, R Abbas, M-L Vo Van and I Bondarenko Br J Cancer 2013 108: 1985-1993; advance online publication, April 30, 2013; 10.1038/bjc.2013.178 Abstract | Full Text Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study T Urup, W Z Pawlak, P M Petersen, H Pappot, M Rørth and G Daugaard Br J Cancer 2013 108: 1994-1997; advance online publication, May 7, 2013; 10.1038/bjc.2013.229 Abstract | Full Text Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours M Millward, C Underhill, S Lobb, J McBurnie, S J Meech, J Gomez-Navarro, M A Marshall, B Huang and C B Mather Br J Cancer 2013 108: 1998-2004; advance online publication, May 7, 2013; 10.1038/bjc.2013.227 Abstract | Full Text Translational Therapeutics Top Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells V Martín, A M Sanchez-Sanchez, F Herrera, C Gomez-Manzano, J Fueyo, M A Alvarez-Vega, I Antolín and C Rodriguez Br J Cancer 2013 108: 2005-2012; advance online publication, April 30, 2013; 10.1038/bjc.2013.188 Abstract | Full Text 212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint K J Yong, D E Milenic, K E Baidoo and M W Brechbiel Br J Cancer 2013 108: 2013-2020; advance online publication, April 30, 2013; 10.1038/bjc.2013.189 Abstract | Full Text Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK Y Storozhuk, S N Hopmans, T Sanli, C Barron, E Tsiani, J-C Cutz, G Pond, J Wright, G Singh and T Tsakiridis Br J Cancer 2013 108: 2021-2032; advance online publication, April 30, 2013; 10.1038/bjc.2013.187 Abstract | Full Text Molecular Diagnostics Top Assessment of DNA methylation status in early stages of breast cancer development A Q van Hoesel, Y Sato, D A Elashoff, R R Turner, A E Giuliano, J M Shamonki, P J K Kuppen, C J H van de Velde and D S B Hoon Br J Cancer 2013 108: 2033-2038; advance online publication, May 7, 2013; 10.1038/bjc.2013.136 Abstract | Full Text Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance C Palmieri, O Gojis, B Rudraraju, C Stamp-Vincent, D Wilson, S Langdon, C Gourley and D Faratian Br J Cancer 2013 108: 2039-2044; advance online publication, May 7, 2013; 10.1038/bjc.2013.199 Abstract | Full Text Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer B Burford, A Gentry-Maharaj, R Graham, D Allen, J W Pedersen, A S Nudelman, O Blixt, E O Fourkala, D Bueti, A Dawnay, J Ford, R Desai, L David, P Trinder, B Acres, T Schwientek, A Gammerman, C A Reis, L Silva, H Osório, R Hallett, H H Wandall, U Mandel, M A Hollingsworth, I Jacobs, I Fentiman, H Clausen, J Taylor-Papadimitriou, U Menon and J M Burchell Br J Cancer 2013 108: 2045-2055; advance online publication, May 7, 2013; 10.1038/bjc.2013.214 Abstract | Full Text ARID1B, a member of the human SWI/SNF chromatin remodeling complex, exhibits tumour-suppressor activities in pancreatic cancer cell lines M Khursheed, J N Kolla, V Kotapalli, N Gupta, S Gowrishankar, S G Uppin, R A Sastry, S Koganti, C Sundaram, J R Pollack and M D Bashyam Br J Cancer 2013 108: 2056-2062; advance online publication, May 9, 2013; 10.1038/bjc.2013.200 Abstract | Full Text Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer S Mitsunaga, M Ikeda, S Shimizu, I Ohno, J Furuse, M Inagaki, S Higashi, H Kato, K Terao and A Ochiai Br J Cancer 2013 108: 2063-2069; advance online publication, April 16, 2013; 10.1038/bjc.2013.174 Abstract | Full Text Genistein downregulates onco-miR-1260b and inhibits Wnt-signalling in renal cancer cells H Hirata, K Ueno, K Nakajima, Z L Tabatabai, Y Hinoda, N Ishii and R Dahiya Br J Cancer 2013 108: 2070-2078; advance online publication, April 16, 2013; 10.1038/bjc.2013.173 Abstract | Full Text Evaluation of a new panel of six mononucleotide repeat markers for the detection of DNA mismatch repair-deficient tumours A Pagin, F Zerimech, J Leclerc, A Wacrenier, S Lejeune, C Descarpentries, F Escande, N Porchet and M-P Buisine Br J Cancer 2013 108: 2079-2087; advance online publication, May 7, 2013; 10.1038/bjc.2013.213 Abstract | Full Text Geographic analysis of RKIP expression and its clinical relevance in colorectal cancer V H Koelzer, E Karamitopoulou, H Dawson, A Kondi-Pafiti, I Zlobec and A Lugli Br J Cancer 2013 108: 2088-2096; advance online publication, April 30, 2013; 10.1038/bjc.2013.197 Abstract | Full Text High levels of cleaved caspase-3 in colorectal tumour stroma predict good survival P Noble, M Vyas, A Al-Attar, S Durrant, J Scholefield and L Durrant Br J Cancer 2013 108: 2097-2105; advance online publication, April 16, 2013; 10.1038/bjc.2013.166 Abstract | Full Text Myofibroblast activation in colorectal cancer lymph node metastases T M Yeung, C Buskens, L M Wang, N J Mortensen and W F Bodmer Br J Cancer 2013 108: 2106-2115; advance online publication, May 7, 2013; 10.1038/bjc.2013.209 Abstract | Full Text Tumour-associated CD66b+ neutrophil count is an independent prognostic factor for recurrence in localised cervical cancer A Carus, M Ladekarl, H Hager, B S Nedergaard and F Donskov Br J Cancer 2013 108: 2116-2122; advance online publication, April 16, 2013; 10.1038/bjc.2013.167 Abstract | Full Text The prognostic significance of vasohibin-1 expression in patients with prostate cancer T Kosaka, Y Miyazaki, A Miyajima, S Mikami, Y Hayashi, N Tanaka, H Nagata, E Kikuchi, K Nakagawa, Y Okada, Y Sato and M Oya Br J Cancer 2013 108: 2123-2129; advance online publication, April 16, 2013; 10.1038/bjc.2013.169 Abstract | Full Text The role of the WNT/β-catenin pathway in central nervous system primitive neuroectodermal tumours (CNS PNETs) H A Rogers, J H Ward, S Miller, J Lowe, B Coyle and R G Grundy Br J Cancer 2013 108: 2130-2141; advance online publication, April 16, 2013; 10.1038/bjc.2013.170 Abstract | Full Text Sox11 expression in astrocytic gliomas: correlation with nestin/c-Met/IDH1-R132H expression phenotypes, p-Stat-3 and survival P Korkolopoulou, G Levidou, E A El-Habr, C Adamopoulos, P Fragkou, E Boviatsis, M S Themistocleous, K Petraki, G Vrettakos, M Sakalidou, V Samaras, A Zisakis, A Saetta, I Chatziandreou, E Patsouris and C Piperi Br J Cancer 2013 108: 2142-2152; advance online publication, April 25, 2013; 10.1038/bjc.2013.176 Abstract | Full Text The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer V Eklöf, M L Wikberg, S Edin, A M Dahlin, B-A Jonsson, Å Öberg, J Rutegård and R Palmqvist Br J Cancer 2013 108: 2153-2163; advance online publication, May 9, 2013; 10.1038/bjc.2013.212 Abstract | Full Text Genetics and Genomics Top Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice L Heinzerling, S Kühnapfel, D Meckbach, M Baiter, E Kaempgen, P Keikavoussi, G Schuler, A Agaimy, J Bauer, A Hartmann, F Kiesewetter and R Schneider-Stock Br J Cancer 2013 108: 2164-2171; advance online publication, April 11, 2013; 10.1038/bjc.2013.143 Abstract | Full Text Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers E H Lips, L Mulder, A Oonk, L E van der Kolk, F B L Hogervorst, A L T Imholz, J Wesseling, S Rodenhuis and P M Nederlof Br J Cancer 2013 108: 2172-2177; advance online publication, April 4, 2013; 10.1038/bjc.2013.144 Abstract | Full Text Low penetrance susceptibility to glioma is caused by the TP53 variant rs78378222 V Enciso-Mora, F J Hosking, A L Di Stefano, D Zelenika, S Shete, P Broderick, A Idbaih, J-Y Delattre, K Hoang-Xuan, Y Marie, M Labussière, A Alentorn, P Ciccarino, M Rossetto, G Armstrong, Y Liu, K Gousias, J Schramm, C Lau, S J Hepworth, M Schoemaker, K Strauch, M Müller-Nurasyid, S Schreiber, A Franke, S Moebus, L Eisele, A Swerdlow, M Simon, M Bondy, M Lathrop, M Sanson and R S Houlston Br J Cancer 2013 108: 2178-2185; advance online publication, April 9, 2013; 10.1038/bjc.2013.155 Abstract | Full Text Letters to the Editor Top Measures of promptness of cancer diagnosis in primary care G Irving and J Holden Br J Cancer 2013 108: 2186; advance online publication, May 2, 2013; 10.1038/bjc.2013.193 Full Text Reply: Timeliness, risk communication and patient preferences for investigations or referral Georgios Lyratzopoulos, Gary A Abel, Sean McPhail, Richard D Neal and Gregory P Rubin Br J Cancer 2013 108: 2187-2188; advance online publication, May 2, 2013; 10.1038/bjc.2013.194 Full Text Comment on ‘Quiescence and γH2AX in neuroblastoma are regulated by Ouabain/Na,K-ATPase’: ouabain and cancer J M Calderón-Montaño, E Burgos-Morón and M López-Lázaro Br J Cancer 2013 108: 2189-2190; advance online publication, May 16, 2013; 10.1038/bjc.2013.234 Full Text Reply: Comment on ‘Quiescence and yH2AX in neuroblastoma are regulated by ouabain/Na,K-ATPase’: ouabain and cancer H Hiyoshi, J I Johnsen, M Andäng and P Uhlén Br J Cancer 2013 108: 2191; advance online publication, May 16, 2013; 10.1038/bjc.2013.235 Full Text Comment on ‘Endocrine therapy in prostate cancer: time for re-appraisal of risks, benefits and cost-effectiveness?’ S I A Shah, P D Abel, R E Langley and F H Cafferty Br J Cancer 2013 108: 2192-2193; advance online publication, April 30, 2013; 10.1038/bjc.2013.210 Full Text Reply: Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness? D J Rosario and L Bourke Br J Cancer 2013 108: 2194; advance online publication, April 30, 2013; 10.1038/bjc.2013.211 Full Text Comment on ‘High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer’ C Ho-Yen, R L Bowen, S Kermorgant and J L Jones Br J Cancer 2013 108: 2195-2196; advance online publication, May 14, 2013; 10.1038/bjc.2013.249 Full Text Advertisement Have you read the top ten minireviews? This top ten charts the minireviews that have been downloaded most often, in HTML or PDF format, from the British Journal of Cancer website recently. It may bring articles to your attention that you might not have otherwise noticed. We hope you enjoy them. Click here   Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.